Analysts Set Nuvalent, Inc. (NASDAQ:NUVL) Price Target at $138.33

Shares of Nuvalent, Inc. (NASDAQ:NUVL) have earned a consensus rating of “Moderate Buy” from the sixteen ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $138.3333.

NUVL has been the topic of a number of research reports. UBS Group reissued a “buy” rating on shares of Nuvalent in a report on Wednesday, December 17th. Stifel Nicolaus boosted their price objective on shares of Nuvalent from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Wedbush reiterated an “outperform” rating and set a $125.00 price objective (up previously from $120.00) on shares of Nuvalent in a research note on Monday, November 17th. HC Wainwright raised their target price on shares of Nuvalent from $130.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, November 17th. Finally, Canaccord Genuity Group assumed coverage on Nuvalent in a report on Wednesday, November 12th. They set a “buy” rating and a $126.00 target price for the company.

Nuvalent Stock Up 9.9%

Shares of Nuvalent stock opened at $106.82 on Thursday. The business has a 50-day moving average price of $102.64 and a 200 day moving average price of $88.91. Nuvalent has a fifty-two week low of $55.53 and a fifty-two week high of $112.88. The firm has a market cap of $7.77 billion, a P/E ratio of -20.08 and a beta of 1.32.

Nuvalent (NASDAQ:NUVL) last issued its quarterly earnings results on Thursday, October 30th. The company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.31). During the same quarter last year, the company posted ($1.28) earnings per share. As a group, equities research analysts anticipate that Nuvalent will post -3.86 earnings per share for the current year.

More Nuvalent News

Here are the key news stories impacting Nuvalent this week:

• Negative Sentiment: CEO James Richard Porter sold 9,543 shares on Jan. 6 at an average $97.16 (≈ $927.2k); his post-sale holding was 278,629 shares (3.31% ownership drop). SEC Filing
• Negative Sentiment: CEO James Richard Porter sold 17,890 shares on Jan. 5 at an average $97.32 (≈ $1.74M); post-sale direct ownership 288,172 shares (5.85% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 81,733 shares (3.75% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 84,914 shares (4.75% ownership drop). SEC Filing
• Negative Sentiment: Insider Christopher Durant Turner sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 55,130 shares (5.46% ownership drop). SEC Filing
• Negative Sentiment: Christopher Durant Turner sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 58,311 shares (6.77% ownership drop). SEC Filing
• Negative Sentiment: Insider Deborah Ann Miller sold 2,589 shares on Jan. 6 at $97.16 (≈ $251.5k); post-sale holding 42,134 shares (5.79% ownership drop). SEC Filing
• Negative Sentiment: Deborah Ann Miller sold 4,363 shares on Jan. 5 at $97.32 (≈ $424.6k); post-sale holding 44,723 shares (8.89% ownership drop). SEC Filing
• Negative Sentiment: Insider Henry E. Pelish sold 2,664 shares on Jan. 6 at $97.17 (≈ $258.9k); post-sale holding 65,888 shares (3.89% ownership drop). SEC Filing
• Negative Sentiment: Henry E. Pelish sold 2,496 shares on Jan. 5 at $97.32 (≈ $242.9k); post-sale holding 68,552 shares (3.51% ownership drop). SEC Filing

Insider Activity

In other Nuvalent news, CEO James Richard Porter sold 27,000 shares of the stock in a transaction on Thursday, October 16th. The stock was sold at an average price of $90.63, for a total value of $2,447,010.00. Following the sale, the chief executive officer directly owned 249,062 shares of the company’s stock, valued at $22,572,489.06. This trade represents a 9.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Alexandra Balcom sold 20,000 shares of the firm’s stock in a transaction on Monday, October 13th. The shares were sold at an average price of $88.51, for a total value of $1,770,200.00. Following the completion of the sale, the chief financial officer owned 61,734 shares in the company, valued at $5,464,076.34. The trade was a 24.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 1,044,224 shares of company stock worth $100,193,914 over the last 90 days. Insiders own 10.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in shares of Nuvalent by 47.6% during the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after buying an additional 108 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new position in Nuvalent during the 3rd quarter worth $38,000. Eastern Bank bought a new position in shares of Nuvalent in the third quarter worth $52,000. Persistent Asset Partners Ltd acquired a new position in shares of Nuvalent during the second quarter valued at $88,000. Finally, Farther Finance Advisors LLC raised its stake in shares of Nuvalent by 9,230.8% during the second quarter. Farther Finance Advisors LLC now owns 1,213 shares of the company’s stock valued at $93,000 after purchasing an additional 1,200 shares in the last quarter. Institutional investors own 97.26% of the company’s stock.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.